Clinical Applications of the Urokinase Receptor (uPAR) for Cancer Patients

Publisher： Bentham Science Publishers

E-ISSN： 1873-4286|17|19|1890-1910

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.17, Iss.19, 2011-06, pp. : 1890-1910

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Urokinase Receptor (uPAR) Ligand based Recombinant Toxins for Human Cancer Therapy

By  

Current Pharmaceutical Design, Vol. 17, Iss. 19, 2011-06 ,pp. : 1979-1983

Bentham Science Publishers

Access to resources Recommend Favorite

Urokinase-type Plasminogen Activator (uPA) and its Receptor (uPAR): Development of Antagonists of uPA / uPAR Interaction and their Effects In Vitro and In Vivo

By  

Current Pharmaceutical Design, Vol. 9, Iss. 19, 2003-07 ,pp. : 1529-1543

Bentham Science Publishers

Access to resources Recommend Favorite

Regulation of the Urokinase Receptor (uPAR) by LDL Receptor-related Protein-1 (LRP1)

By  

Current Pharmaceutical Design, Vol. 17, Iss. 19, 2011-06 ,pp. : 1962-1969

Bentham Science Publishers

Access to resources Recommend Favorite

Rational Targeting of the Urokinase Receptor (uPAR): Development of Antagonists and Non-Invasive Imaging Probes

By  

Current Drug Targets, Vol. 12, Iss. 12, 2011-01 ,pp. : 1711-1728

Bentham Science Publishers

Access to resources Recommend Favorite

Development of Novel Therapeutics Targeting the Urokinase Plasminogen Activator Receptor (uPAR) and Their Translation Toward the Clinic

By  

Current Pharmaceutical Design, Vol. 17, Iss. 19, 2011-06 ,pp. : 1970-1978

Bentham Science Publishers

Access to resources Recommend Favorite